Cargando…
Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3
We have obtained the 1.7 Å crystal structure of FIV protease (PR) in which 12 critical residues around the active site have been substituted with the structurally equivalent residues of HIV PR (12X FIV PR). The chimeric PR was crystallized in complex with the broad-based inhibitor TL-3, which inhibi...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781954/ https://www.ncbi.nlm.nih.gov/pubmed/17212810 http://dx.doi.org/10.1186/1742-4690-4-1 |
_version_ | 1782132003971268608 |
---|---|
author | Heaslet, Holly Lin, Ying-Chuan Tam, Karen Torbett, Bruce E Elder, John H Stout, C David |
author_facet | Heaslet, Holly Lin, Ying-Chuan Tam, Karen Torbett, Bruce E Elder, John H Stout, C David |
author_sort | Heaslet, Holly |
collection | PubMed |
description | We have obtained the 1.7 Å crystal structure of FIV protease (PR) in which 12 critical residues around the active site have been substituted with the structurally equivalent residues of HIV PR (12X FIV PR). The chimeric PR was crystallized in complex with the broad-based inhibitor TL-3, which inhibits wild type FIV and HIV PRs, as well as 12X FIV PR and several drug-resistant HIV mutants [1-4]. Biochemical analyses have demonstrated that TL-3 inhibits these PRs in the order HIV PR > 12X FIV PR > FIV PR, with K(i )values of 1.5 nM, 10 nM, and 41 nM, respectively [2-4]. Comparison of the crystal structures of the TL-3 complexes of 12X FIV and wild-typeFIV PR revealed theformation of additinal van der Waals interactions between the enzyme inhibitor in the mutant PR. The 12X FIV PR retained the hydrogen bonding interactions between residues in the flap regions and active site involving the enzyme and the TL-3 inhibitor in comparison to both FIV PR and HIV PR. However, the flap regions of the 12X FIV PR more closely resemble those of HIV PR, having gained several stabilizing intra-flap interactions not present in wild type FIV PR. These findings offer a structural explanation for the observed inhibitor/substrate binding properties of the chimeric PR. |
format | Text |
id | pubmed-1781954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-17819542007-01-26 Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3 Heaslet, Holly Lin, Ying-Chuan Tam, Karen Torbett, Bruce E Elder, John H Stout, C David Retrovirology Research We have obtained the 1.7 Å crystal structure of FIV protease (PR) in which 12 critical residues around the active site have been substituted with the structurally equivalent residues of HIV PR (12X FIV PR). The chimeric PR was crystallized in complex with the broad-based inhibitor TL-3, which inhibits wild type FIV and HIV PRs, as well as 12X FIV PR and several drug-resistant HIV mutants [1-4]. Biochemical analyses have demonstrated that TL-3 inhibits these PRs in the order HIV PR > 12X FIV PR > FIV PR, with K(i )values of 1.5 nM, 10 nM, and 41 nM, respectively [2-4]. Comparison of the crystal structures of the TL-3 complexes of 12X FIV and wild-typeFIV PR revealed theformation of additinal van der Waals interactions between the enzyme inhibitor in the mutant PR. The 12X FIV PR retained the hydrogen bonding interactions between residues in the flap regions and active site involving the enzyme and the TL-3 inhibitor in comparison to both FIV PR and HIV PR. However, the flap regions of the 12X FIV PR more closely resemble those of HIV PR, having gained several stabilizing intra-flap interactions not present in wild type FIV PR. These findings offer a structural explanation for the observed inhibitor/substrate binding properties of the chimeric PR. BioMed Central 2007-01-09 /pmc/articles/PMC1781954/ /pubmed/17212810 http://dx.doi.org/10.1186/1742-4690-4-1 Text en Copyright © 2007 Heaslet et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Heaslet, Holly Lin, Ying-Chuan Tam, Karen Torbett, Bruce E Elder, John H Stout, C David Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3 |
title | Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3 |
title_full | Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3 |
title_fullStr | Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3 |
title_full_unstemmed | Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3 |
title_short | Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3 |
title_sort | crystal structure of an fiv/hiv chimeric protease complexed with the broad-based inhibitor, tl-3 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781954/ https://www.ncbi.nlm.nih.gov/pubmed/17212810 http://dx.doi.org/10.1186/1742-4690-4-1 |
work_keys_str_mv | AT heasletholly crystalstructureofanfivhivchimericproteasecomplexedwiththebroadbasedinhibitortl3 AT linyingchuan crystalstructureofanfivhivchimericproteasecomplexedwiththebroadbasedinhibitortl3 AT tamkaren crystalstructureofanfivhivchimericproteasecomplexedwiththebroadbasedinhibitortl3 AT torbettbrucee crystalstructureofanfivhivchimericproteasecomplexedwiththebroadbasedinhibitortl3 AT elderjohnh crystalstructureofanfivhivchimericproteasecomplexedwiththebroadbasedinhibitortl3 AT stoutcdavid crystalstructureofanfivhivchimericproteasecomplexedwiththebroadbasedinhibitortl3 |